Guidelines

Long-Term ASCVD Risk Drives Expanded Statin Eligibility By 2026 Dyslipidemia Guideline

Nearly 25 million more adults in the U.S. are eligible for statin therapy, based on recommendations in the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline, compared with the previous guideline, according to original research published Aug. 12 in JACC.

ACC CardiaCast: Risk Assessment and Treatment of Hypertriglyceridemia

This episode of CardiaCast will feature a discussion on risk assessment and the treatment of hypertriglyceridemia.

GBD Study 2023: LDL-C Burden Increasing Globally

The global burden attributable to elevated LDL-C has grown substantially since 1990, driven largely by population growth and aging despite significant declines in age-standardized rates, according to findings from the Global Burden of Disease Study 2023 (GBD 2023) Cholesterol Collaborators published July 29 in JAMA.

Independent study: Nearly 1 in 3 U.S. adults with high blood pressure may need medication

A study evaluating the American Heart Association/American College of Cardiology 2025 guideline on high blood pressure found that among 81 million U.S. adults with high blood pressure and no cardiovascular disease, nearly 23

2024 European Society of Cardiology guidelines for the management of chronic coronary syndromes

This article discusses the updated 2024 European Society of Cardiology guidelines on chronic coronary syndromes and situates them within the context of Dutch clinical practice. A working group was appointed by the Netherlands Society of Cardiology (Nederlandse Vereniging voor Cardiologie). It consisted of a general cardiologist, interventional cardiologists, cardiovascular imaging cardiologists, and a representative of the Dutch Heart Foundation (Nederlandse Hartstichting).

The CARDIOLIPID Plan: A Cardiovascular Risk-centred Implementation Framework for the Diagnosis and Management of Dyslipidaemia: Experts’ Proposal

Dyslipidaemia remains a major contributor to cardiovascular morbidity and mortality, despite the availability of effective lipid-lowering therapies and well-established European Society of Cardiology/European Atherosclerosis Society guidelines. In clinical practice, the implementation of these recommendations is often suboptimal, with persistent therapeutic inertia and fragmented decision-making processes.

Beyond therapeutic maximalism: Prioritization and personalization in preventive therapies

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)

Heart failure (HF) remains a pressing health concern, with rising prevalence globally. Subjectivity and ambiguity in the definition of HF and its antecedent stages have limited research, global surveillance, and prevention programs. To address this, several cardiac societies and foundations convened to standardize the definition of HF in 2021 and designated stage B or pre-HF to identify individuals at risk of developing HF.

Development, validation, translation and user testing of a patient information leaflet for the management of dyslipidemia

Non-adherence is the main problem among dyslipidemia patients. Patient information leaflets are educational tools designed to improve patients' knowledge and understanding of their condition and treatment, which may indirectly support better medication use. The aim of this study was to prepare, validate, translate, and user-testing of Patient information leaflets (PIL) for dyslipidemia patients.

First-ever guideline on cardiovascular-kidney-metabolic syndrome issued

The first-ever clinical practice guideline on cardiovascular-kidney-metabolic (CKM) syndrome from the American Heart Association and the American College of Cardiology details staging to assess how a person’s kidneys, metabolism

New guideline reframes weight as health risk tied to diabetes, kidney and heart conditions

Story Highlights The first guideline for cardiovascular-kidney-metabolic syndrome (CKM syndrome), published today by American Heart Association and the American College of Cardiology, identifies obesity as a key metabolic factor in the syndrome’s

First-Ever Guideline Addresses CKM Syndrome

The new 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome is the first ever to address the "interrelated condition characterized by the interconnections among metabolic risk factors (including obesity and type 2 diabetes)

2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

AIM: The "2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome" retires, replaces, and expands upon the "2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults." The primary intended audience for this guideline is clinicians who care for patients across the spectrum of cardiovascular-kidney-metabolic syndrome, an interrelated condition characterized by the interconnections among metabolic…

Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology

Current clinical practice guidelines for the primary prevention of cardiovascular disease recommend risk assessment to align the type and intensity of preventive efforts with an individual's risk. The 2025 American Heart Association/American College of Cardiology guideline for the prevention, detection, evaluation, and management of high blood pressure in adults and the 2026 American Heart Association/American College of Cardiology guideline on the management of dyslipidemia incorporate…

2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome

Perimenopause may offer a “window of opportunity” for heart disease prevention in women

Women should undergo screening for cardiovascular risk factors throughout adulthood, however, perimenopause, which is the transition into menopause, offers a “window of opportunity” to reassess risk and prompt lifestyle changes,

Gum disease may be linked to plaque buildup in arteries, higher risk of major CVD events

DALLAS, Dec. 16, 2025 — There is increasing evidence that gum disease is associated with increased risk of cardiovascular events, including heart attack, stroke, atrial fibrillation, heart failure and cardiometabolic health conditions. Effective